BrandEseence

TCR Therapies Market

TCR Therapies Market Size, Share & Trends Analysis Report

TCR Therapies Market: Global Industry Analysis 2015 To 2020 And Opportunity Assessment 2021 To 2027

Published
Report ID : BMRC 1551
Number of pages : 300
Published Date : Nov 2022
Category : Healthcare
Delivery Timeline : 48 hrs
Single User : $3250

Corporate User : $7999

Global TCR Therapy Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027. Increased need of TCR therapies for cancer patients and effectiveness of TCR therapies against cancer are the major factors driving the growth of Global TCR Therapy Market.

Scope of Global TCR Therapy Market Report

T-cell receptors (TCRs) are proteins that recognize small protein fragments (peptides) on the surface of antigen-presenting cells. Each T cell has its own TCR, which is generated by randomly assorting genes. In 2017, approvals for genetically engineered T cell therapies were granted. TCR Therapies include taking T cells from patients and equipping them with a new T cell receptor that allows them to target particular cancer antigens in addition to stimulating and extending the available anti-tumor T cells. The treatment can be more tailored to individuals by allowing doctors to select an optimum goal for each patient's tumor and distinct types of T cells to engineer. This, in turn, could give patients more hope for relief. Activated T cells are given unique receptors that target their complementary cancer antigens in engineered TCR therapy. This dramatically improves treatment personalization and increases the likelihood of positive health outcomes. TCR therapy is a more flexible treatment option that can be used to treat a wider range of cancers. The advancement of techniques to reduce the time it takes to separate T cells and the creation of low-cost separation equipment might actually open more market growth opportunities.

People were forced to stay indoors during the Covid-19 pandemic, and as a result of the lockout, medical treatments and facilities, as well as diagnostic methods and cancer surgeries, were delayed thus, it has shown a decline impact on the market growth of TCR therapy. Despite of that, the ability of TCR-T cell immunotherapy for COVID-19 regulation is being investigated by researchers at Duke-NUS Medical School in Singapore. The TCR therapy in Covid-19 treatment success may increase chances of growth in market of TCR therapies.

Global TCR Therapy Market report is segmented on the basis of type, application, end-user and region & country level. Based upon type, Global TCR Therapy Market is classified into transduction of chimeric antigen receptors and transduction of TCR α/β heterodimer. Based on application, the market is divided into refractory relapsed melanoma, synovial sarcoma, multiple myeloma, lung cancer and other. Based upon end-user, the market is divided into hospitals, clinics & ambulatory centers, cancer research institutes and others.

Global TCR Therapy Market Segmentation:

By Type:

  • Transduction of Chimeric Antigen Receptor
  • Transduction of TCR α/β Heterodimer

By Application:

  • Refractory Relapsed Melanoma
  • Synovial Sarcoma
  • Multiple Myeloma
  • Lung Cancer
  • Other

By End-User:

  • Hospitals
  • Clinics & Ambulatory Centers
  • Cancer Research Institutes
  • Others

The regions covered in Global TCR Therapy Market report are North America, Europe, Asia-Pacific, Latin America and Rest of the World. On the basis of country level, the market of global TCR therapies is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, South East Asia, Middle East Asia (UAE, Egypt, Saudi Arabia) GCC, Africa, etc.

Key Players for Global TCR Therapy Market Report:

Some key players for Global TCR Therapy Market are Adaptimmune Therapeutics PLC, Immunocore, Medigene, Adaptive Biotechnologies, Lion TCR, TCR2 Therapeutics, Inc., RootPath, Kite Pharma, Guangzhou Xiangxue Pharmaceutical Co., Ltd, Eureka Therapeutics and others.

News: T-TCR cure's Therapy will be developed by Immunotech in China.

January 20th, 2020; T-Cure Bioscience has entered into a license agreement with Immunotech Biopharm in China for the research and production of T-800TCR Cure's candidate, a HERV-E-targeting T-cell receptor (TCR) therapeutic for renal cell cancer. Via a structured joint research and development arrangement, T-Cure is currently developing 800TCR in the United States in partnership with the National Heart, Lung, and Blood Institute (NHLBI). The candidate is being tested in a phase I test at NHLBI for the treatment of metastatic clear cell renal cell carcinoma that has failed to respond to angiogenic and checkpoint inhibitors. HERV-E targets, according to T-Cure, are a new frontier of TCR targets with significant clinical potential for cancer immunotherapy. Immunotech will pay T-Cure an upfront payment, as well as future development milestone payments and tiered royalties based on net sales of the drug. In China, Immunotech will have the exclusive rights to grow and market 800TCR.

Increased need of TCR Therapies for Cancer patients and Effectiveness of TCR Therapies against Cancer Driving the Market Growth

The major factor driving the growth of Global TCR Therapy Market is increasing need of TCR Therapies for cancer patients. TCR-T-cell therapy has advanced quickly and has emerged as a promising treatment option for a variety of cancers, especially solid tumors. Cancers of the lung, breast, prostate, colon, and rectum, as well as bladder cancers, are classified as solid tumors. According to Journal of Technology in Cancer Research and Treatment, TCRs work by interacting with peptide-major histocompatibility complexes (pMHC), which are complexes formed by peptide bound to MHC. pMHCs are formed when intracellular antigens are broken up into peptide chains and displayed by MHC molecules. Proteolysis cleaves cytoplasmic proteins to be expressed by class I MHC proteins into peptide chains, the majority of which are defective ribosomal translation products. These peptides are then bound to class I MHC proteins, which are found on the cell surface of all nucleated cells. Antigen-presenting cells (APCs) are cells that express class II MHC proteins. They use endocytosis to internalize foreign material proteins and cleave them into peptide chains that can bind to class II MHC proteins. T-cell receptors, which must be matched to patients' human leukocyte antigen (HLA) alleles, identify these pMHCs and cause cancer cell death. Thus, the increasing number of cancer patient’s demands need of TCR Therapies. For instance, according to WHO, in 2018, 18.1 million people worldwide were diagnosed with cancer, with 9.6 million deaths from it. Lung cancer is the most commonly diagnosed cancer (11.6% of all cases), followed by female breast cancer (11.6%) and colorectal cancers (10.2%). Lung cancer is the most common cause of cancer death (18.4% of all deaths), followed by colorectal (9.2%) and stomach cancers (8.2%).

In addition, effectiveness of TCR therapies against cancer is also fostering the market growth. TCR-T has a wide range of applications that could make it a highly effective immunotherapy for cancer patients, including improved efficacy, increased TCR affinity, increased TCR expressions, and increased protection. For instance, according to Journal of Annals of Blood, TCR-T clinic trials revealed that improved affinity TCR-T provided 80% clinical responses in advanced myeloma patients. Patients in the clinical trial received five days of chemotherapy and two days of RT to prepare their immune systems for receiving MART-1 and gp100 unique TCR-T cells. Combining chemotherapy/radiation with TCR-T resulted in the creation of more effective cancer ACT therapies.

However, high cost of equipments used for TCR therapies and extra time consumed for separation of T cells for TCR therapies may hamper the market growth. In spite of that, increased efficiency and assuring more safety to the patients can offer more opportunities for the further growth of the global TCR technologies market.

North America is Anticipated to Dominate the Global TCR Therapy Market

The Global TCR Therapy Market is segmented into North America, Europe, Asia-Pacific Latin America and Middle East & Africa. North America is expected to dominate the Global TCR Therapy Market within the forecast period owing to the increasing number of cancer cases and growing demand of TCR therapies for treating the solid tumors rather than CAR-T methods in this region. For instance, according to American Cancer Society Inc., at least 42% newly diagnosed cancers in the United States. The rate was at about 750,000 cases in 2020. Cancer is the leading cause of death in the working-age population in the United States (ages 20-65 years). According to Journal of Technology in Cancer Research & Treatment, in the United States in 2018, melanoma accounted for nearly 92 percent of new cases of skin cancer and 69 percent of skin cancer-related deaths. The second category includes leukemia and gastrointestinal cancers, which is the subject of 24 studies. Just 34 (approximately 16%) of the 210 cancers mentioned in 84 clinical trials are hematological malignancies, and 84 percent of the cancer types targeted by these 84 clinical trials are solid tumors. Maybe since CAR-T has already shown its efficacy in treating hematological malignancies, while its effects on solid tumors have been shown to be ineffective in comparison to TCR-T-cell therapy in numerous studies.

Asia Pacific is expected to witness a significant growth in the global TCR  therapy market owing to the growing prevalence of cancer infected people in this region. For instance; according to Chinese Journal of Cancer Research, in 2017 cancer caused about 62.9 million disability-adjusted life years (DALYs) in China. The most significant contribution was made by solid tumor cancers such as lung cancer, which was followed by liver cancer, stomach cancer, and esophageal cancer.

Report Analysis Details
Historical data 2015 - 2020
Forecast Period 2021 - 2027
Market Size in 2020: XX
Base year considered 2020
Forecast Period CAGR %:

XX %

Market Size Expected in 2027: XX
Tables, Charts & Figures: 175
Pages 200
Key Players/Companies Adaptimmune Therapeutics PLC, Immunocore, Medigene, Adaptive Biotechnologies, Lion TCR, TCR2 Therapeutics, Inc., RootPath, Kite Pharma, Guangzhou Xiangxue Pharmaceutical Co., Ltd, Eureka Therapeutics and others
Segments Covered By Type, By Application, By End-User
Regional Analysis North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa

Key Benefits for Global TCR Therapy Market Report:

  • Global TCR Therapy Market report covers in-depth historical and forecast analysis.
  • Global TCR Therapy Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.
  • Global TCR Therapy Market report helps to identify opportunities in the marketplace.
  • Global TCR Therapy Market report covers extensive analysis of emerging trends and competitive landscape.

TCR Therapy Market By Regional & Country Level:

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • France
  • Germany
  • Italy

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

Latin America

  • Brazil
  • Mexico

Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa

 

SUMMARY
VishalSawant
Vishal Sawant
Busines Development
vishal@brandessenceresearch.com
+91 8830 254 358

+44-1173181773

sales@brandessenceresearch.com

We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us hr@brandessenceresearch.com

JOIN US

LONDON OFFICE

BrandEssence® Market Research and Consulting Pvt ltd.

Kemp House, 152 - 160 City Road, London EC1V 2NX

FOLLOW US

Twitter
Facebook
LinkedIn
Skype
YouTube

CONTACT US

1-888-853-7040 - U.S. (TOLL FREE)
+44-1173181773 - U.K. OFFICE
+91-7447409162 - INDIA OFFICE

© Copyright 2022-23 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®

PaymentModes